Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers
Source: SeekingAlpha
2026-01-15 07:10:00 ET
More on Disc Medicine, Sanofi, etc.
- Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Sanofi multiple sclerosis therapy rejected by the FDA
- Sanofi, Regeneron’s Dupixent approved in Japan for children with asthma
Read the full article on Seeking Alpha
For further details see:
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers
Disc Medicine Inc.
NASDAQ: IRON
IRON Trading
-2.4% G/L:
$59.34 Last:
105,695 Volume:
$60.54 Open:
IRON Latest News
March 14, 2026 05:39:00 pm
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
March 04, 2026 01:26:00 pm
Securities Investigation: Levi & Korsinsky Investigates Disc Medicine, Inc. (IRON) on Behalf of Investors
February 26, 2026 08:30:00 am
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
IRON Stock Data
$2,821,824,610
32,299,039
0.06%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
